U.S. Markets closed

Critical Outcome Technologies Inc. (COT.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
1.27-0.14 (-9.93%)
At close: 3:56PM EDT
People also watch
IMM.VDMA.VCZO.VCOV.VELEZF
Full screen
Previous Close1.41
Open1.45
Bid1.25 x
Ask1.40 x
Day's Range1.27 - 1.45
52 Week Range1.27 - 8.00
Volume16,825
Avg. Volume22,498
Market Cap18.94M
Beta1.45
PE Ratio (TTM)-2.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research5 months ago

    The Appointment of New CEO is Supposed to Bring COT.V to a New Level

    In early December 2016, Critical Outcome Technologies (COT.V) (COTQF) appointed Alison Silva as the Company’s new Chief Executive Officer (CEO) effective January 1, 2017. Ms. Silva served before the appointment on the Board of Directors and as President. Alison has worked with COT.V in various roles since 2013, during which time she has been integral in shaping the Company’s orphan drug development strategy.

  • Zacks Small Cap Research11 months ago

    COTI Exited Fiscal 2016 with a Relatively Strong Balance Sheet

    The higher R&D expenses for the quarter were primarily due to the addition of clinical trial expenses, whereas there was no comparable expense in the same quarter of FYE 2015. The addition of clinical trial expenses was partially offset by a reduction in synthesis and miscellaneous R&D expenses with much of this reduction related to consulting fees incurred in writing and conducting additional tests in support of the IND submission to the FDA which occurred late in the fourth quarter of FYE 2015. The Company (COT.V) reported a quarterly net loss of $2.4 million ($0.02 per share) for fiscal 4Q16, compared to a net loss of $0.95 million ($0.01 per share) for the fourth quarter of the previous year.

  • Zacks Small Cap Researchlast year

    COTI: Balance Sheet Boosted by New Financings

    By Grant Zeng, CFA TSX:COT.V On March 17 , 2016, COTI (TSX:COT.V) announced that it realized gross proceeds of $1,447,125 upon the exercise of 4,823,750 common share purchase warrants that would otherwise ...